Neelu Puri

2.2k total citations
43 papers, 1.8k citations indexed

About

Neelu Puri is a scholar working on Molecular Biology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neelu Puri has authored 43 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 15 papers in Physiology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neelu Puri's work include Telomeres, Telomerase, and Senescence (14 papers), Lung Cancer Treatments and Mutations (12 papers) and RNA Interference and Gene Delivery (10 papers). Neelu Puri is often cited by papers focused on Telomeres, Telomerase, and Senescence (14 papers), Lung Cancer Treatments and Mutations (12 papers) and RNA Interference and Gene Delivery (10 papers). Neelu Puri collaborates with scholars based in United States, India and Netherlands. Neelu Puri's co-authors include Maria Ruden, Ravi Salgia, Barbara A. Gilchrest, Mark S. Eller, Salman Ahmed, Ramasamy Jagadeeswaran, Abburi Ramaiah, Gagan Chhabra, Srijayaprakash Uppada and Osvaldo Zumba and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Neelu Puri

41 papers receiving 1.8k citations

Peers

Countries citing papers authored by Neelu Puri

Since Specialization

Citations

This map shows the geographic impact of Neelu Puri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neelu Puri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neelu Puri more than expected).

Fields of papers citing papers by Neelu Puri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neelu Puri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neelu Puri. The network helps show where Neelu Puri may publish in the future.

Co-authorship network of co-authors of Neelu Puri

This figure shows the co-authorship network connecting the top 25 collaborators of Neelu Puri. A scholar is included among the top collaborators of Neelu Puri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neelu Puri. Neelu Puri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 428: The role of sphingosine kinase 2 in overcoming EGFR-tyrosine kinase inhibitor resistance, EMT and NSCLC tumor progression 2023 ·Cancer Research ·(unknown), (unknown), Katie Lam, (unknown), Neelu Puri	1
2	PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC 2023 ·Cancers ·(unknown), (unknown), (unknown), Emma Harper, (unknown), (unknown), (unknown), (unknown), (unknown), Neelu Puri	5
3	EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer 2020 ·Therapeutic Advances in Medical Oncology ·Zachary Crees, (unknown), Leo Lin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas J. Smith, (unknown), (unknown), Odile David, Neelu Puri	11
4	Potential Telomere-Related Pharmacological Targets 2020 ·Current Topics in Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Rachel J. Miller, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Neelu Puri	13
5	Abstract 2965: Induction of DNA damage responses by T-oligo and 6-thio-dG via modulating telomere associated proteins and telomerase 2019 ·Cancer Research ·(unknown), Nabiha Khan, (unknown), (unknown), (unknown), Neelu Puri	2
6	Oligonucleotides Targeting Telomeres and Telomerase in Cancer 2018 ·Molecules ·(unknown), Nabiha Khan, (unknown), (unknown), Rachel J. Miller, (unknown), (unknown), (unknown), Neelu Puri	37
7	Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance 2018 ·Cancers ·(unknown), Gagan Chhabra, Leo Lin, (unknown), (unknown), Nabiha Khan, (unknown), (unknown), Rachel J. Miller, Neelu Puri	111
8	Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC 2018 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Neelu Puri	39
9	Mechanism of Action of G-Quadruplex–Forming Oligonucleotide Homologous to the Telomere Overhang in Melanoma 2017 ·Journal of Investigative Dermatology ·Gagan Chhabra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Benjamin E. Ramirez, Neelu Puri	19
10	Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer 2016 ·Biochemical and Biophysical Research Communications ·Ichwaku Rastogi, (unknown), Andrew I. Webb, Gagan Chhabra, (unknown), Brian Webb, Neelu Puri	31
11	Current Molecularly Targeting Therapies in NSCLC and Melanoma 2015 ·Anti-Cancer Agents in Medicinal Chemistry ·(unknown), Ichwaku Rastogi, (unknown), (unknown), (unknown), Leo Lin, B Sheu, (unknown), (unknown), Neelu Puri	10
12	Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer 2015 ·PLoS ONE ·(unknown), Ichwaku Rastogi, Gagan Chhabra, (unknown), Neelu Puri	40
13	Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy 2014 ·Current Pharmaceutical Design ·Zachary Crees, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Amanda Stone, Srijayaprakash Uppada, (unknown), Neelu Puri	32
14	T-oligo as an anticancer agent in colorectal cancer 2014 ·Biochemical and Biophysical Research Communications ·(unknown), Amanda Stone, Nan Sethakorn, Srijayaprakash Uppada, (unknown), Marc Bissonnette, Neelu Puri	17
15	Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy 2013 ·International Journal of Nanomedicine ·Neelu Puri, Srijayaprakash Uppada, (unknown), (unknown), (unknown), Ziyuan Song, Jianjun Cheng	19
16	Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides 2013 ·Cancer Letters ·Neelu Puri, (unknown), (unknown), (unknown), Audra N. Iness, (unknown), Yutong Zhao, Ravi Salgia	20
17	Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer 2008 ·Journal of Carcinogenesis ·Neelu Puri, Ravi Salgia	171
18	c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma 2007 ·Clinical Cancer Research ·Neelu Puri, Salman Ahmed, Varalakshmi Janamanchi, Maria Tretiakova, Osvaldo Zumba, Thomas Krausz, Ramasamy Jagadeeswaran, Ravi Salgia	129
19	Induction of Apoptosis by Telomere 3′ Overhang-Specific DNA 2002 ·Experimental Cell Research ·Mark S. Eller, Neelu Puri, Ina Hadshiew, Suraj Venna, Barbara A. Gilchrest	64
20	Basic fibroblast growth factor promotes melanin synthesis by melanocytes 1996 ·Archives of Dermatological Research ·Neelu Puri, (unknown), (unknown), Syed S. Asghar, (unknown), Abburi Ramaiah, W. Westerhof	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact